Research programme: eye disorder therapeutics - Kamat Pharmatech

Drug Profile

Research programme: eye disorder therapeutics - Kamat Pharmatech

Latest Information Update: 15 Nov 2016

Price : $50

At a glance

  • Originator Kamat Pharmatech
  • Class Anti-inflammatories; Ciclosporins
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dry eyes; Inflammation

Most Recent Events

  • 15 Nov 2016 Preclinical trials in Dry eyes in USA (Ophthalmic)
  • 15 Nov 2016 Preclinical trials in Inflammation in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top